IWP-2

目录号：S7085 Purity: 99.60%

IWP-2是一种Wnt信号和分泌抑制剂，无细胞试验中IC50为27 nM，选择性阻断Porcn介导的Wnt棕榈酰化，一般不影响Wnt/β-catenin，且对Wnt刺激的细胞反应没有影响。IWP-2可特定低抑制 CK1δ。

IWP-2 Chemical Structure

CAS: 686770-61-6

规格	价格	库存
10mg	806.41	现货
50mg	2766.42	现货
1g	24488.1	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.60%

99.60

常与IWP-2一起在实验中被使用的化合物

IWP-4

IWP-2和IWP-4是WNT抑制剂，通常用作人类心肌细胞(CM)分化的小分子。

Moon SH, et al. Int J Stem Cells. 2017 May 30;10(1):1-11.

LGK-974

IWP-2和LGK-974降低RWPE-1和PZ-HPV7敲低(KD)细胞中CD44的球体形成和转录活性。

Yun EJ, et al. Clin Cancer Res. 2016 Feb 1;22(3):670-9.

PRI-724

IWP-2和PRI-724诱导细胞凋亡，影响HNSCC细胞迁移，并强烈影响HNSCC细胞中β-catenin依赖性基因的表达。

Kleszcz R, et al. Cell Oncol (Dordr). 2019 Aug;42(4):505-520.

VPA (Valproic acid)

IWP-2促进肠上皮细胞分化，Valproicacid抑制Lgr5+干细胞分化。

Yin X, et al. Nat Methods. 2014 Jan;11(1):106-12.

IWP-2相关产品

相关靶点	WNT β-catenin Wnt/β-catenin	点击展开
相关产品	IWR-1-endo SKL2001 BML-284 (Wnt agonist 1) PRI-724 Salinomycin (from Streptomyces albus) FH535 PNU-74654 LF3 KYA1797K KY02111 iCRT3 Adavivint (SM04690) MSAB Isoquercitrin IQ-1 iCRT14 CCT251545 Isoxazole 9 (ISX-9) JW55 Methyl Vanillate M435-1279 WAY-262611 JW74	点击展开
相关化合物库	激酶抑制剂库 FDA药物库干细胞小分子化合物库 GPCR小分子化合物库干细胞分化化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	孵育时间	活性描述	文献信息
mouse L cells	Function assay	24 h	Inhibition of porcupine-mediated Wnt signalling in mouse L cells after 24 hrs by SpringerImages-Topflash reporter assay, EC50=30 nM	23477365
HEK293T	Function assay	22 hrs	Inhibition of porcupine in HEK293T cells transfected with Wnt3A-expressing vector assessed as suppression of Wnt/beta-catenin signaling after 22 hrs by Super-top flash reporter gene assay, IC50 = 0.157 μM.	29630366
MIAPaCa2	Antiproliferative assay	48 hrs	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay, EC50 = 1.9 μM.	29630366
SW620	Antiproliferative assay	48 hrs	Antiproliferative activity against human SW620 cells after 48 hrs by MTT assay, EC50 = 1.9 μM.	29630366
Capan1	Antiproliferative assay	48 hrs	Antiproliferative activity against human Capan1 cells after 48 hrs by MTT assay, EC50 = 2.05 μM.	29630366
PANC1	Antiproliferative assay	48 hrs	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay, EC50 = 2.33 μM.	29630366
HEK293	Antiproliferative assay	48 hrs	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay, EC50 = 2.76 μM.	29630366
Panc89	Antiproliferative assay	48 hrs	Antiproliferative activity against human Panc89 cells after 48 hrs by MTT assay, EC50 = 3.86 μM.	29630366
HT-29	Antiproliferative assay	48 hrs	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay, EC50 = 4.67 μM.	29630366
A818-6	Antiproliferative assay	48 hrs	Antiproliferative activity against human A818-6 cells after 48 hrs by MTT assay, EC50 = 8.96 μM.	29630366
A673	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Saos-2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-12	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
BT-12	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	29435139
DAOY	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	29435139
Rh41	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
A673	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
MG 63 (6-TG R)	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
fibroblast cells	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	29435139
Rh41	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
SJ-GBM2	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
LAN-5	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
SK-N-MC	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
TC32	qHTS assay		qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

靶点

Wnt ^[1] (Cell-free assay)	^M82FCK1δ ^[3] (Cell-free assay)
27 nM	40 nM

体外研究(In Vitro)
体外研究活性	IWP-2在再生医学和抗癌方面都非常有效。IWP-2使Porcn失活, Porcn是一种与O-酰基转移酶(MBOAT)结合的膜,且选择性抑制Wnt棕榈酰化。IWP-2抑制Lrp6受体和Dvl2发生Wnt依赖性的磷酸化，也抑制β-catenin累积。^[1]
实验图片	检测方法	检测指标	实验图片	PMID
实验图片	Western blot	Wnt5-a/b / β-catenin / Axin2 c-myc / Cyclin D1 / Survivin MMP7		27119499

参考文献
[1] Chen B, et al. Nat Chem Biol, 2009, 5(2), 100-107. [2] Castellana D, et al. PLoS Biol. 2014, 12(12):e1002002. [3] Balbina García-Reyes, et al. J Med Chem . 2018 May 10;61(9):4087-4102.

参考文献

化学信息&溶解度

分子量	466.6	分子式	C₂₂H₁₈N₄O₂S₃
CAS号	686770-61-6	SDF	Download IWP-2 SDF
Smiles	CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMF : 12.5 mg/mL (26.78 mM)

DMSO : 10 mg/mL ( (21.43 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

DMF : 20 mg/mL (42.86 mM) Warmed with 50°C water bath; Ultrasonicated;

DMSO : 3 mg/mL ( (6.42 mM) Warmed with 50°C water bath; Ultrasonicated; ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

DMSO : 3 mg/mL ( (6.42 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

IWP-2

产品质控

常与IWP-2一起在实验中被使用的化合物

IWP-2相关产品

相关信号通路图

细胞实验数据示例

生物活性

化学信息&溶解度

实验计算

技术支持